A 67-year-old G1P1 is evaluated for a two-week history of mild pelvic cramping and scant, brownish vaginal discharge. Her last menstrual period was 15 years ago. Her medical history includes severe osteoporosis, for which she takes raloxifene, and hypothyroidism, for which she takes levothyroxine. Her BMI is 22 kg/m². On speculum examination, the vaginal mucosa appears pale and thin, with a small amount of old blood in the vaginal vault and at the cervical os. Bimanual examination reveals a small, anteverted uterus and no adnexal masses. Transvaginal ultrasonography demonstrates a homogeneously thickened endometrium measuring 6 mm. Which of the following is the most appropriate next step in management?
- Endometrial biopsyAnswer
- BApplication of topical vaginal estrogen
- CDiscontinuation of raloxifene and clinical observation
- DSaline infusion sonohysterography
- EMeasurement of serum CA-125 levels
Answer
Endometrial biopsy
The correct approach for evaluating postmenopausal bleeding involves either an initial endometrial biopsy or a transvaginal ultrasound (TVUS). If TVUS is performed and reveals an endometrial thickness greater than 4 mm, an endometrial biopsy is mandatory to obtain a histologic diagnosis. Despite the patient exhibiting physical signs of atrophic vaginitis and taking a medication that does not increase endometrial cancer risk (raloxifene), the objective finding of a 6 mm endometrial stripe requires direct tissue sampling to definitively rule out endometrial carcinoma.
Step-by-Step Solution
Key Concept
In a postmenopausal woman presenting with vaginal bleeding, an endometrial thickness greater than 4 mm on transvaginal ultrasound absolutely mandates an endometrial biopsy to rule out malignancy, regardless of coexisting benign findings such as atrophic vaginitis.